Skip to main content
ConductScienceScienceDex

James E Kirby

From the FY2026 NIH awards this investigator leads as contact PI. The department is the award's.

FY2026 NIH rank #14,882
Unclaimed recordClaim profile
  • R01 Holder
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 1873165Search this ID in NIH RePORTER
ORCID iD
No ORCID iD on recordA researcher can add one by claiming this profile.
ScienceDex PI coverage
FY2024 through FY2026Career claims are limited to the years shown.

NIH Funding · FY2026

Linked Award Amount
$1.3M
Full award amounts, FY2026
Award Records
2
Records listing this PI
Award-Linked Rank
#14,882
By linked amount among FY2026 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for James E Kirby. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2026 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2026 award records by amount

NIH award records listing James E Kirby as a PI. Multi-PI records show the full award amount for context.

  • 1R01AI195600-01A1R01Contact PI
    Structure-guided design of apramycin analogs to avoid resistance and enhance efficacy
    Beth Israel Deaconess Medical Center · Pathology (investigator's affiliation)
    $844.9K
    award amount
  • 1R21AI199146-01R21Contact PI
    Development of next generation spectinomycin analogs that evade modifying enzyme-based resistance and show enhanced potency against multidrug-resistant pathogens.
    Beth Israel Deaconess Medical Center · Pathology (investigator's affiliation)
    $493.9K
    award amount

Award organization

Organizations that administered FY2026 awards listing James E Kirby as a PI.

FY2026 award administered by Beth Israel Deaconess Medical Center (MA).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    Beth Israel Deaconess Medical Center
  2. 2024
    $500K Cumulative Funding
  3. 2025
    $1M Cumulative Funding
  4. 2025
    R01 Grant Holder
  5. 2026
    $2M Cumulative Funding

Shared-award investigators

Other investigators listed on at least one of the same NIH award records as James E Kirby.

Edward W Yu
Beth Israel Deaconess Medical Center
2
shared awards
George A O'Doherty
Beth Israel Deaconess Medical Center
2
shared awards
Roman Manetsch
Beth Israel Deaconess Medical Center
1
shared award

Explore further

Find collaborators for James E Kirby

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →